2018
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
Flaig T, Spiess P, Agarwal N, Bangs R, Boorjian S, Buyyounouski M, Downs T, Efstathiou J, Friedlander T, Greenberg R, Guru K, Hahn N, Herr H, Hoimes C, Inman B, Jimbo M, Kader A, Lele S, Meeks J, Michalski J, Montgomery J, Pagliaro L, Pal S, Patterson A, Petrylak D, Plimack E, Pohar K, Porter M, Preston M, Sexton W, Siefker-Radtke A, Tward J, Wile G, Johnson-Chilla A, Dwyer M, Gurski L. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 1041-1053. PMID: 30181416, DOI: 10.6004/jnccn.2018.0072.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAftercareBCG VaccineChemotherapy, AdjuvantCystectomyHumansLymphatic MetastasisMedical OncologyNeoadjuvant TherapyNeoplasm StagingOrgan Sparing TreatmentsPatient SelectionQuality of LifeRadiotherapy, AdjuvantRandomized Controlled Trials as TopicSocieties, MedicalTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsBladder cancerTreatment of muscle-invasive bladder cancerImmune checkpoint inhibitor therapyMuscle-invasive bladder cancerNCCN Clinical Practice GuidelinesFollow-up of patientsAJCC Cancer Staging ManualCheckpoint inhibitor therapyCancer Staging ManualNCCN Guidelines InsightsClinical practice guidelinesMetastatic diseaseInhibitor therapyStaging ManualTreatment optionsFollow-upCancerBladderPractice guidelinesPatientsNCCNTreatmentAJCCTherapyGuidelines
2017
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.
Wierda W, Zelenetz A, Gordon L, Abramson J, Advani R, Andreadis C, Bartlett N, Byrd J, Caimi P, Fayad L, Fisher R, Glenn M, Habermann T, Harris N, Hernandez-Ilizaliturri F, Hoppe R, Horwitz S, Kaminski M, Kelsey C, Kim Y, Krivacic S, LaCasce A, Martin M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad A, Snyder E, Sokol L, Swinnen L, Vose J, Yahalom J, Dwyer M, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 293-311. PMID: 28275031, DOI: 10.6004/jnccn.2017.0030.Peer-Reviewed Original ResearchConceptsSmall lymphocytic lymphomaChronic lymphocytic leukemiaTreatment of patientsNCCN Clinical Practice GuidelinesCD20 monoclonal antibodyNCCN Guidelines InsightsClinical practice guidelinesRelapsed/refractory CLL/SLLChemoimmunotherapy regimensLymphocytic lymphomaCritical signaling pathwaysLymphocytic leukemiaSmall molecule inhibitorsCLL/SLLBcl-2 familyBcl-2Monoclonal antibodiesMolecule inhibitorsSignaling pathwayPractice guidelinesPatientsNCCNTreatmentLymphomaRegimens